Use of Bortezomib in recurrent and refractory multiple myeloma and impaired renal function

被引：0
|
作者：
Falcone, A. [1 ]
Sanpaolo, G. [1 ]
Bodenizza, C. [1 ]
Carella, A. M. [1 ]
Dell'Olio, M. [1 ]
Mantuano, S. [1 ]
Melillo, L. [1 ]
Merla, E. [1 ]
Scalzulli, F. [1 ]
Cascavilla, N. [1 ]
机构：
[1] IRCCS Casa Sollievo Sofferenza, San Giovanni Rotondo, Italy
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2007年 / 92卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：233 / 233
页数：1
相关论文
共 50 条
  • [41] Improvement in renal function in patients with multiple myeloma and impaired renal function receiving novel agent induction therapies
    Li, Liang
    Hu, Shuai
    Zhu, Hao
    Wang, Yaning
    Ma, Lian
    Booth, Brian P.
    Rahman, Nam Atiqur
    Schwartz, Janice
    Blumenthal, Gideon
    Liu, Qi
    CANCER RESEARCH, 2020, 80 (16)
  • [42] Bendamustine-bortezomib-dexamethasone in relapsed/refractory multiple myeloma.
    Cerchione, Claudio
    Nappi, Davide
    Cangini, Delia
    Ronconi, Sonia
    Ceccolini, Michela
    Musuraca, Gerardo
    Martinelli, Giovanni
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [43] Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma
    Yee, Andrew J.
    Laubach, Jacob P.
    Campagnaro, Erica L.
    Lipe, Brea C.
    Nadeem, Omar
    Friedman, Robb S.
    Cole, Craig E.
    O'Donnell, Elizabeth K.
    Bianchi, Giada
    Branagan, Andrew R.
    Schlossman, Robert L.
    Shapiro, Samantha J.
    Harrington, Cynthia C.
    Burke, Jill N.
    Gammon, Marilyn T.
    Lively, Kathleen J.
    Reimonn, Cassandra A.
    Andrade, Danielle X.
    Redd, Robert
    Lohr, Jens G.
    Anderson, Kenneth C.
    Richardson, Paul G.
    Raje, Noopur S.
    BLOOD ADVANCES, 2025, 9 (05) : 1163 - 1170
  • [44] Visceral leishmaniasis infection in a refractory multiple myeloma patient treated with bortezomib
    Eugenio Piro
    Mariagrazia Kropp
    Renato Cantaffa
    Angelo Giuseppe Lamberti
    Guido Carillio
    Stefano Molica
    Annals of Hematology, 2012, 91 : 1827 - 1828
  • [45] BENDAMUSTINE-BORTEZOMIB-DESAMETASONE IN THE MANAGEMENT OF RELAPSED AND REFRACTORY MULTIPLE MYELOMA
    Cerchione, C.
    Catalano, L.
    Pareto, A. E.
    Basile, S.
    Marano, L.
    Peluso, I.
    Simeone, L.
    Vitagliano, O.
    Palmieri, S.
    Rocco, S.
    Ferrara, F.
    Pane, F.
    HAEMATOLOGICA, 2017, 102 : 796 - 796
  • [46] Bortezomib in relapsed or refractory multiple myeloma:: results in a cohort of 39 patients
    Canovas Fernandez, A.
    Alonso Alonso, J. J.
    Barreiro Garcia, J. G.
    Aguirre Errasti, C.
    REVISTA CLINICA ESPANOLA, 2008, 208 (04): : 187 - 192
  • [47] Combined administration of bortezomib and dexamethasone in the treatment of refractory multiple myeloma (MM)
    Sagristani, M.
    Gonnella, F.
    Esposito, M.
    Improta, S.
    Lucania, A.
    Villa, M. R.
    Mastrullo, L.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 144 - 144
  • [48] Visceral leishmaniasis infection in a refractory multiple myeloma patient treated with bortezomib
    Piro, Eugenio
    Kropp, Mariagrazia
    Cantaffa, Renato
    Lamberti, Angelo Giuseppe
    Carillio, Guido
    Molica, Stefano
    ANNALS OF HEMATOLOGY, 2012, 91 (11) : 1827 - 1828
  • [49] Clinical Outcome of Bortezomib Retreatment in Patients with Relapsed or Refractory Multiple Myeloma
    Ahn, Jae-Sook
    Jung, Sung-Hoon
    Lee, Seung-Shin
    Ahn, Seo-Yeon
    Yang, Deok-Hwan
    Kim, Yeo-Kyeoung
    Kim, Hyeoung-Joon
    Lee, Je-Jung
    BIOMED RESEARCH INTERNATIONAL, 2014, 2014
  • [50] Update on the optimal use of bortezomib in the treatment of multiple myeloma
    Mohan, Meera
    Matin, Aasiya
    Davies, Faith E.
    CANCER MANAGEMENT AND RESEARCH, 2017, 9 : 51 - 63
12345